Boundless Bio, Inc. Cybersecurity Tracker
Cybersecurity Tracker for Boundless Bio, Inc. including cybersecurity governance, scorecard, incidents and more.
- Cybersecurity Governance (2)
- Cybersecurity Incidents (0)
- Regulatory Actions
- Litigation
- Corporate Governance
- Company
Cybersecurity Governance
Additional cybersecurity governance available.
| Filing Date | Source |
|---|---|
| 2026-03-09 | SEC 10-K |
| 2025-03-27 | SEC 10-K |
Cybersecurity Incidents
No incidents found.
Regulatory Actions Coming Soon
SEC enforcement actions, FTC orders, and state regulatory proceedings coming soon.
Additional regulatory actions
Litigation Coming Soon
Cybersecurity-related lawsuits, class actions, and settlements coming soon.
Additional litigation
Corporate Governance Coming Soon
Board directors, committees, and auditor details coming soon.
Additional corporate governance
Company
Profile
Boundless Bio, Inc. is a clinical-stage oncology company developing ecDNA-directed small molecule therapeutics (ecDTx) using its proprietary Spyglass discovery platform and an ecDNA diagnostic (ECHO); its lead candidate is BBI-355, an oral CHK1 inhibitor in Phase 1/2 clinical trials.
| Name | Boundless Bio, Inc. |
|---|---|
| Headquarters | California; U.S.A |
| Employees | 64 |
| Revenue | Unknown |
| Industry | Biotechnology |
| Sector | Healthcare |
| Ticker | BOLD |
| CIK | 1782303 |
| Website | https://boundlessbio.com/ |
| Category | Non-accelerated Filer |
| Fiscal Year End | December 31 |
Relationships
No known relationships.